Activates All Australian Phase Iia Trial Sites For ONP-002. Oragenics (NYSE American: OGEN) announced that all three sites in its Australian Phase IIa clinical trial of ONP-002 for mild traumatic brai ...

Oragenics Inc (NASDAQ:OGEN) shares are trading lower by 21% to $1.03 during Tuesday’s session after the company announced a proposed public offering. The company earlier Tuesday announced a placement ...

Oragenics, Inc. (OGEN) is currently conducting a Phase 2 clinical trial of its lead development compound AG013 in the prevention of severe oral mucositis (OM). AG013 is an oral mouth rinse composed of ...

Oragenics Inc (NASDAQ:OGEN) shares are trading lower by 45.5% to $0.58 during Wednesday’s session after the company announced a $4.45 million public offering of 8,106,584 shares at $0.55 per share.

On May 4, 2020, Oragenics, Inc. (OGEN) announced the acquisition of Noachis Terra Inc., which is developing TerraCoV2, a vaccine candidate against SARS-CoV-2 (the virus that causes COVID-19) that is ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

The nonprofit Ogen Group lent a record $50 million to individuals, families, nonprofit organizations and businesses across Israel in 2020, as the pandemic wreaked havoc on the economy, shutting down ...